President Trump Directs FDA to Accelerate Psychedelic Drug Review

U.S. President Donald Trump has issued an executive order instructing the Food and Drug Administration to quicken its review process for certain psychedelic drugs, such as ibogaine. This initiative aims to enhance access to research and potential treatments utilizing these substances, particularly for conditions like post-traumatic stress disorder. The move, supported by veteran organizations and the Health Secretary, represents a notable regulatory shift that could influence future clinical practices and patient options for mental health care.